Search

Displaying results 2751 - 2760 of 6076 in total
  1. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    Acemetacin is a carboxymethyl ester of indometacin. It is a potent non-steroidal anti-inflammatory drug, derived from the indol-3-acetic acid, whose activity is thought to be mainly through its active metabolite indomethacin. In clinical...

  2. Drug

    Terconazole

    go.drugbank.com/drugs/DB00251
    Approved

    [A178093]Due to the existence of 2 stereocentres, there are 4 possible stereoisomers for terconazole.

  3. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    Conventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported

  4. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [L5971] However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.[L5974]

    Categories: Antidepressive Agents Indicated for Depression
  5. Drug

    Trimethobenzamide

    go.drugbank.com/drugs/DB00662
    ApprovedInvestigational

    Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic respon...

    Categories: Antihistamines for Systemic Use
  6. Drug

    Atractylodes japonica root oil

    go.drugbank.com/drugs/DB11270
    ApprovedWithdrawn

    It is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation.

  7. Drug

    Piperaquine

    go.drugbank.com/drugs/DB13941
    ApprovedInvestigational

    Eurartesim was first authorized for market by the European Medicines Agency in October 2011.

  8. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and

  9. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic

  10. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.